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Abstract
The distribution of the different subtypes of HIV varies from one region of the world to another. Subtype B is predominant in Europe and
the USA, but there has been a gradual increase in non-B subtypes as a result of migration from regions where they are endemic, and this
may have important implications for the control of HIV-1. The aim of this study was to assess the prevalence of HIV-1 subtypes in an
urban area of northern Italy in the period 1997–2008. Forty-nine (12.2%; 95% CI, 9.00–15.40) of 401 patients investigated carried a non-B
subtype, the prevalence of which was 7.7% (95% CI, 4.96–10.44) among native Italians and 55.3% (95% CI, 39.49–71.11) among non-Italians,
1.6% (95% CI, 0.00–3.81) among ex-intravenous drug addicts, 7.6% (95% CI, 1.21–13.99) among homosexual/bisexual men and 20.5% (95%
CI, 14.83–26.17) among heterosexuals, 6.8% (95% CI, 3.37–10.23) among Italians infected as a result of sexual contacts in Italy, and 55.0%
(95% CI, 33.20–76.80) among Italians infected abroad or by foreign partners. Overall prevalence increased from 2.9% (95% CI, 0.00–6.11)
before 1993 to 23.0% (95% CI, 16.31–29.69) in the period 2001–2008. The results demonstrate that there has been an increase in non-B
subtypes (especially sexually transmitted infections), particularly among patients infected abroad or by foreign partners.
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Introduction
Type 1 human immunodeﬁciency virus (HIV-1) is character-
ized by a wide range of genetic variability and, by means of
phylogenetic analyses, has been classiﬁed into three distinct
groups: M (major), O (outlier) and N (not M, not O). Group
M is responsible for most of the infections in the world, and
groups O and N for infections in limited regions of central
Africa. Group M includes nine subtypes (AD, FH, J and K)
[1] with genetic differences of 25–35% between them at the
level of the env gene and 15% at the gag gene [2]. Analyses
of the entire viral sequence have also led to the characteriza-
tion of inter-subtype recombinants, which probably
originated in individuals infected with two or more subtypes.
The term circulating recombinant forms (CRFs) is used
when an identical recombinant is isolated in at least three
epidemiologically unrelated individuals [3].
The distribution of the subtypes and CRFs varies in differ-
ent regions of the world [4,5]: subtype B predominates in
North America, Western Europe and Oceania; subtype A in
Eastern Europe and Central Asia; subtype C in South Africa,
India and Ethiopia; subtype D in North Africa; and subtype G
in West Africa. The other subtypes are mainly present (albeit
in a minority) in Latin America and Eastern Europe (F), and
Central Africa (F, H, J) [4]. CRFs are responsible for a large
proportion of infections in some geographical regions, such
as CRF01_AE in Southeast Asia and CRF02_AG in Central
and West Africa [4].
There have been reports of associations between the dif-
ferent subtypes/recombinants and transmission routes. Sub-
type B is the most highly represented in Western countries,
where HIV-1 initially manifested mainly in risk groups such as
intravenous drug users (IVDUs) and men who have sex with
men (MSM), whereas the other subtypes (particularly A and
C) are more represented in developing countries, where
transmission is primarily heterosexual [6]. Even within the
same region, the subtypes may be segregated into different
risk groups: for example, subtype B in IDVUs and CRF01_AE
in heterosexuals has been reported in Thailand [7], and
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subtype B in MSM and subtype C in heterosexuals in South
Africa [8]. However, more important than a close link
between a speciﬁc subtype and a route of transmission is
determining the arrival of a subtype in a geographical area
via a particular route of transmission, as subtype A spread
among heterosexuals in Africa but among IVDUs in Eastern
Europe. Changes in the route of transmission can also lead
to epidemiological changes within the same population, as
has been observed in Thailand where the original subtype B
present in IVDUs has gradually been supplanted by
CRF01_AE as a result of sexual transmission [9,10].
In Europe and the USA, where the predominant subtype
B was historically introduced by IDVUs and MSMs, non-B
subtypes and CRFs have become more frequent as a result
of migration and sexual contacts between Europeans and
people coming from regions in which non-B subtypes are
endemic [11–16].
This has a number of implications because the different
subtypes of HIV-1 may lead to differences in the progression
to AIDS [17,18], although this is still controversial because the
results of some studies have not been conﬁrmed by others
[19]. However, there do seem to be signiﬁcant differences in
the use of the CCR5 and CXCR4 co-receptors, and in the
ability to induce syncytia [20]. In therapeutic terms, the differ-
ent subtypes seem to have the same susceptibility to antiviral
drugs [21], but some seem to produce mutations faster than
others [22]. Subtype C seems to be naturally resistant to non-
nucleoside reverse transcriptase inhibitors (NNRTIs) [23],
whereas subtype G is less susceptible to protease inhibitors
(PIs) in vitro [24].
The increasing circulation of new subtypes may therefore
have major effects on controlling HIV-1, thus making public
health surveillance increasingly important. The aim of this
study was to assess the prevalence of the subtypes of HIV-1
(group M) in HIV-positive subjects in an urban area of north-
ern Italy.
Materials and Methods
The study was based on samples taken from 401 HIV-1 posi-
tive subjects (278 men and 123 women, average age
40.7 years, range 14–70), which were received between
1997 and 2008 for the detection of resistance to antiretrovi-
ral drugs. At the time of collection, 159 patients (39.7%)
were naı¨ve and 242 (60.3%) had experienced treatment fail-
ure; 363 (90.5%) of the patients were Italian and 38 (9.5%)
of foreign origin.
In order to search for resistance to antiretroviral drugs,
HIV-RNA was extracted, reverse transcribed, ampliﬁed and
sequenced using a commercial kit (TRUGENE HIV-1 Geno-
typing kit; Siemens, Tarrytown, NY, USA) in accordance with
the manufacturer’s instructions. The nucleotide sequence
was sent by computer to the database of the American
National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/projects/genotyping/form-
page.cgi) for subtyping.
The patients’ medical records were consulted in order to
record transmission routes, the probable geographical origin
of the infection, and the date of the ﬁrst detection of anti-
HIV antibodies.
Fisher’s exact test and the v2 test were used to analyse
the data statistically.
Results
Three hundred and ﬁfty-two samples (87.8% with a 95% conﬁ-
dence interval (CI) between 84.60 and 91.00) showed subtype
B, and 49 (12.2%; 95% CI, 9.00–15.40) non-B subtypes, of
which 18 (36.7%; 95% CI, 23.20–50.20) were CRFs. The differ-
ences between men and women were not statistically signiﬁ-
cant except in the case of CRF02_AG (p <0.01) (Table 1).
The subtypes were divided on the basis of the patients’
nationality. The prevalence of non-B subtypes was 7.7% (95%
CI, 4.96–10.44) among native Italians and 55.3% (95% CI:
39.49–71.11) among non-Italians. The differences in the
prevalence of the subtype among the patients of Italian and
foreign origin were all statistically signiﬁcant except for sub-
types C and F (Table 1).
Non-B subtypes were found in the samples of 12.0% (95%
CI, 2.99–21.01) of the patients aged <30 years and in 22.8%
(95% CI, 11.91–33.69) of those aged more than 50 years
(Table 2). The difference between the patients aged £50 and
>50 years was statistically signiﬁcant (p <0.05).
The probable route of infection was available in 390 cases:
in 124 (31.8%) the infection was due to the shared use of
syringes among IVDUs; in 261 (69.9%) it was due to sexual
contacts (195 heterosexuals, 60 MSM and six bisexuals); in
three (0.8%) it was due to vertical transmission; in one
(0.3%) it was due to blood transfusion; and in one (0.3%) it
was due to tattooing. The prevalence of the HIV-1 subtypes
in these patients is shown in Table 3. The difference
between the ex-IVDUs and all of the subjects infected as a
result of sexual contacts (heterosexual, MSM/bisexual) was
statistically signiﬁcant (p <0.01).
All of the non-Italian patients were infected as a result of
sexual contacts.
The date of the ﬁrst positive HIV antibody test was avail-
able in 382 cases, and was used to estimate the assumed
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period of HIV infection. Table 4 shows the prevalence of the
subtypes by period of infection, stratiﬁed by risk factor. The
differences between the various periods were not statistically
signiﬁcant except in the case of heterosexuals between the
periods 1993 to 2000 and after 2000. All of the subjects with
a non-B subtype who were infected before 1993 were Italian
(two men and one woman).
The probable geographical origin of the infection was
available in the case of 227 Italian patients (202 B and 25
non-B subtypes) infected as a result of sexual contacts (168
heterosexual, ﬁve bisexual and 54 MSM). Two hundred and
seven patients (193 B and 14 non-B subtypes) were infected
in Italy and 20 (nine B and 11 non-B subtypes) infected
abroad or after sexual contacts in Italy with partners from
abroad. The difference between the prevalence of non-B
subtypes among the patients who contracted the infection in
Italy (6.8%; 95% CI, 3.37–10.23) and those who contracted it
abroad or with foreign partners (55.0%; 95% CI, 33.20–
76.80) was statistically signiﬁcant (p <0.01). The difference is
statistically signiﬁcant (p <0.01) in the case of heterosexuals
TABLE 1. HIV-1 subtypes in patients, by gender and nationality
HIV-1 subtypes
HIV-1 positive patients
Gender
p
Nationality
p TotalMale Female Italian Foreign
B 247 (88.8%)
95% CI: 85.09–92.51
105 (85.4%)
95% CI: 79.16–91.64
NS 335 (92.3%)
95% CI: 89.56–95.04
17 (44.7%)
95% CI: 28.89–60.51
<0.01 352 (87.8%)
95% CI: 84.60–91.00
C 3 (1.1%)
95% CI: 0.00–2.33
1 (0.8%)
95% CI: 0.00–2.37
NS 3 (0.8%)
95% CI: 0.00–1.72
1 (2.6%)
95% CI: 0.00–7.66
NS 4 (1.0%)
95% CI: 0.03–1.97
F 18 (6.5%)
95% CI: 3.60–9.40
4 (3.3%)
95% CI: 0.14–6.46
NS 19 (5.2%)
95% CI: 2.92–7.48
3 (7.9%)
95% CI: 0.00–16.48
NS 22 (5.5%)
95% CI: 3.27–7.73
G 2 (0.7%)
95% CI: 0.00–1.68
3 (2.4%)
95% CI: 0.00–5.10
NS 2 (0.6%)
95% CI: 0.00–1.39
3 (7.9%)
95% CI: 0.00–16.48
<0.01 5 (1.2%)
95% CI: 0.13–2.27
CRF01_AE 2 (0.7%)
95% CI: 0.00–1.68
1 (0.8%)
95% CI: 0.00–2.37
NS 1 (0.3%)
95% CI: 0.00–0.86
2 (5.3%)
95% CI: 0.00–12.42
<0.05 3 (0.7%)
95% CI: 0.00–1.52
CRF02_AG 3 (1.1%)
95% CI: 0.00–2.33
8 (6.5%)
95% CI: 2.14–10.86
<0.01 2 (0.6%)
95% CI: 0.00–1.39
9 (23.7%)
95% CI: 10.18–37.22
<0.01 11 (2.7%)
95% CI: 1.11–4.29
CRF12_BF 3 (1.1%)
95% CI: 0.00–2.33
1 (0.8%)
95% CI: 0.00–2.37
NS 1 (0.3%)
95% CI: 0.00–0.86
3 (7.9)
95% CI: 0.00–16.48
<0.01 4 (1.0%)
95% CI: 0.03–1.97
Total 278 123 363 38 401
NS, not signiﬁcant; CI, conﬁdence interval.
TABLE 2. HIV-1 subtypes in patients, by age
HIV-1 subtypes
Age classes (years)
£30 31–40 41–50 >50 p £50 vs >50
B 44 (88.0%)
95% CI: 78.99–97.01
147 (88.0%)
95% CI: 83.07–92.93
117 (92.1%)
95% CI: 87.41–96.79
44 (77.2%)
95% CI: 66.31–88.09
<0.05
Non-B 6 (12.0%)
95% CI: 2.99–21.01
20 (12.0%)
95% CI: 7.07–16.93
10 (7.9%)
95% CI: 3.21–12.59
13 (22.8%)
95% CI: 11.91–33.69
Total 50 167 127 57
CI, conﬁdence interval.
TABLE 3. HIV-1 subtypes in patients, by transmission route
HIV-1 subtypes
HIV-1 positive patients
Ex-IVDUs Heterosexuals MSM/bisexuals Othersa Total
B 122 (98.4%)
95% CI: 96.19–100.0
155 (79.5%)
95% CI: 73.83–85.17
61 (92.4%)
95% CI: 86.01–98.79
4 (80.0%)
95% CI: 44.94–100.0
342 (87.7%)
95% CI: 84.44–90.96
Non B 2 (1.6%)
95% CI: 0.00–3.81
40 (20.5%)
95% CI: 14.83–26.17
5 (7.6%)
95% CI: 1.21–13.99
1 (20.0%)
95% CI: 0.00–55.06
48 (12.3%)
95% CI: 9.04–15.56
Total 124 195 66 5 390
CI, conﬁdence interval.
aThree vertical, one transfusional, one through tattooing.
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(6.7%; 95% CI, 2.69–10.71 vs 57.9%; 95% CI, 35.70–80.10)
but not in the case of MSM/bisexuals (6.9%; 95% CI, 0.38–
13.42 vs 0%; 95% CI, 0.00–0.00).
Discussion
HIV-1 infection in Italy spread in the early 1980s, especially
among IVDUs and MSM. As in the USA and other countries
of Western Europe, the B subtype predominated. The num-
ber of heterosexuals infected has gradually increased over
time: data from the Italian Ministry of Health shows that the
percentage of AIDS cases among heterosexuals rose from
14.8% before 1997 to 44.7% in 2007–2008 (among MSM, the
increase was from 15.5% to 22.9%) [25]. The proportion of
foreigners with a new diagnoses of HIV infection increased
from 11% in 1992 to 32.0% in 2007 and, among them, het-
erosexual contacts represent the most frequent form of
transmission [25]. During this period, Italy experienced a
substantial increase in immigration, especially from countries
outside the European Community. The ﬂow of immigrants in
2008 was estimated to be approximately 350 000 people,
leading to an approximately 6% prevalence of foreign citizens
resident in Italy [26].
The immigration of people from countries with a high
prevalence of non-B subtypes has led to the circulation of
new subtypes in Italy, as in the rest of Europe [12,13,27]. A
total of 12.2% of the patients in this study were infected with
a non-B subtype, particularly F1 and CRFs (which account
for about one-third of all non-B subtypes). This is in line with
the ﬁndings of studies carried out elsewhere in Italy, where
the observed prevalence ranges from 4% to 12.6%
[14,28,29], but lower than in other European countries
where the prevalence of non-B subtypes is as high as 20–
40% [16,30]. The prevalence of non-B subtypes among the
Italian patients included in this study was much lower (7.7%)
than among non-Italians (55.3%), who therefore represent a
considerable reservoir for the sexual transmission of non-B
subtypes. Heterosexual contacts were the most important
route of transmission, accounting for all of the infections in
non-Italians; among the Italians, the prevalence of non-B
subtypes was higher among heterosexuals than MSM and
ex-IVDUs (mainly among heterosexuals infected abroad or in
Italy by partners from abroad). Furthermore, the prevalence
of non-B subtypes among heterosexuals increased from 2.9%
before 1993 to 23.0% after 2000.
One limitation of the ﬁndings of this study is that the
absence of seroconversion data (except in very few cases)
means that the ﬁrst positive HIV antibody test was used as a
surrogate for the date of infection, which may actually haveT
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occurred much earlier in some cases (which means the entry
of non-B subtypes into Italy may also have been earlier).
However, as the same approach was used for all of the study
periods, the trend is plausible and consistent with the ﬁnd-
ings of other studies [14].
The fact that the percentage of non-B subtypes among
MSM has not changed over time may indicate a degree of
stability in their sexual behaviour. Among the ex-IVDUs,
non-B subtypes were only observed in two patients, both of
whom were infected before 1993. However, it must be
remembered that in Italy the number of new infections
among IVDUs decreased from 69.0% to 8.6% of all new
cases between 1985 and 2007, whereas the cases attribut-
able to sexual transmission (heterosexual and MSM/bisexual)
increased from 13.3% to 73.7% [25]. According to the Italian
National Statistics Ofﬁce, the majority of subjects with HIV
infection are no longer young IVDUs but mature adults
infected as a result of heterosexual contacts (i.e. the group
in which we found the highest percentage of non-B sub-
types).
In conclusion, the prevalence of non-B subtypes is
increasing in this area of Italy because of the increase in
the number of immigrants (including those with new HIV
infections) and increased sexual transmission between them
and Italians. Given this increase in the prevalence of non-B
subtypes, greater efforts should be made to explore
their biological characteristics and clinical implications, par-
ticularly as a greater number of older people will be
affected.
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